Media Coverage

Our President and CEO Amy Tseng, was featured in El Diario de las Americas. In her interview, Amy speaks on what it means to be a woman CEO, how women must put in extra effort to stand out in the corporate world, and how she believes that equal pay amongst genders can be achieved.

Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech was awarded a group purchasing agreement with Premier, Inc. and The Resource Group on April 1, 2021.

Bio-Tissue announced the case series outcome of surgical repair of large macular holes using AmnioGraft Cryopreserved Amniotic Membrane. Results have shown that the placement of AmnioGraft may be a feasible alternative to conventional surgical methods to improve anatomic and visual outcomes.

Our primary goal is to be the industry leader in birth tissue regenerative medicine—driving our transition from a leader in the tissue space to an emerging biotech company.

Since its inception in 1997, TissueTech has been a pioneer in the clinical application of human birth tissues. The company’s products have been used in more than 500,000 human transplants across multiple indications, under the regulatory classification of human cell and tissue products (HCT/Ps).

Amy Tseng heads up the biotech company TissueTech, which received $110 million in funding. Her background is in business and finance, and she has a keen eye for a profitable opportunity. She likes to keep R&D pipelines fully loaded to identify new markets for “leveraging our core technology.”

Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company involved in the research of the clinical application of human birth tissue-based products, announced today that Yun Guan, MD, PhD, professor of anesthesiology and critical care medicine, and professor of neurological surgery at the Johns Hopkins University School of Medicine, has been awarded a 5-year R01 grant […]

Amniox is currently focusing its research efforts on clinical trials to show an investigational form of their umbilical cord product can potentially help patients with chronic, complex wounds.

Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from a single-center, prospective, investigator-initiated pilot study titled “Injectable Amniotic Membrane/Umbilical Cord Particulate for Knee Osteoarthritis.”

Build a better regenerative medicine app, says TissueTech, and stem cells and their progeny will beat a path to its decellularized matrix…